Share on StockTwits

LipoScience (NASDAQ:LPDX) issued its quarterly earnings data on Monday. The company reported ($0.13) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.19) by $0.06, Analyst Ratings Network reports.

A number of analysts have recently weighed in on LPDX shares. Analysts at Zacks upgraded shares of LipoScience from a “neutral” rating to an “outperform” rating in a research note on Friday, April 11th. They now have a $3.30 price target on the stock. On a related note, analysts at Barclays cut their price target on shares of LipoScience from $7.00 to $5.00 in a research note on Monday, March 17th. Finally, analysts at UBS AG cut their price target on shares of LipoScience from $7.00 to $6.50 in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock.

Shares of LipoScience (NASDAQ:LPDX) traded down 0.63% during mid-day trading on Monday, hitting $3.16. The stock had a trading volume of 47,741 shares. LipoScience has a 52 week low of $2.92 and a 52 week high of $7.37. The stock has a 50-day moving average of $3.24 and a 200-day moving average of $3.9. The company’s market cap is $48.1 million.

LipoScience, Inc is a vitro diagnostic company. The Company’s diagnostic test, the nuclear magnetic resonance (NASDAQ:LPDX) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.